Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
Public ClinicalTrials.gov record NCT00257192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
Study identification
- NCT ID
- NCT00257192
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 284 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2006 (Type not available)
- Primary completion
- Mar 2009 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Mar 25, 2021
2006 – 2009
United States locations
- U.S. sites
- 46
- U.S. states
- 19
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35205 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294-4400 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | Stanford | California | 94305 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80045 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Pfizer Investigational Site | Altamonte Springs | Florida | 32701 | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33301 | — |
| Pfizer Investigational Site | North Miami | Florida | 33161 | — |
| Pfizer Investigational Site | Orange City | Florida | 32763 | — |
| Pfizer Investigational Site | Tampa | Florida | 33613 | — |
| Pfizer Investigational Site | Tavares | Florida | 32778 | — |
| Pfizer Investigational Site | Smyrna | Georgia | 30080 | — |
| Pfizer Investigational Site | Tucker | Georgia | 30084 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96813 | — |
| Pfizer Investigational Site | Des Plaines | Illinois | 60016 | — |
| Pfizer Investigational Site | Oakbrook Terrace | Illinois | 60181 | — |
| Pfizer Investigational Site | Schaumburg | Illinois | 60194 | — |
| Pfizer Investigational Site | Pikesville | Maryland | 21208 | — |
| Pfizer Investigational Site | Towson | Maryland | 21204 | — |
| Pfizer Investigational Site | Towson | Maryland | 21286 | — |
| Pfizer Investigational Site | Clinton Township | Michigan | 48038 | — |
| Pfizer Investigational Site | Meridian | Mississippi | 39301 | — |
| Pfizer Investigational Site | Bridgeton | Missouri | 63044-2588 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Lincoln | Nebraska | 68510 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | Buffalo | New York | 14209 | — |
| Pfizer Investigational Site | Buffalo | New York | 14215 | — |
| Pfizer Investigational Site | Rochester | New York | 14618 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45224 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45229 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73101 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73107 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73116 | — |
| Pfizer Investigational Site | Arlington | Texas | 76011 | — |
| Pfizer Investigational Site | DeSoto | Texas | 75115 | — |
| Pfizer Investigational Site | Plano | Texas | 75093 | — |
| Pfizer Investigational Site | Bothell | Washington | 98011 | — |
| Pfizer Investigational Site | Spokane | Washington | 99204 | — |
| Pfizer Investigational Site | Spokane | Washington | 99216 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53226 | — |
| Pfizer Investigational Site | West Allis | Wisconsin | 53227 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00257192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00257192 live on ClinicalTrials.gov.